Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib

PURPOSE: Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF), which slows disease progression. Management of patients with IPF receiving nintedanib can be complicated by tolerability issues, comorbidities, and concomitant medications. We developed consensus recommendations on...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahaghi, Franck, Belperio, John A, Fitzgerald, John, Gulati, Mridu, Hallowell, Robert, Highland, Kristin B, Huie, Tristan J, Kim, Hyun J, Kolb, Martin, Lasky, Joseph A, Southern, Brian D, Swigris, Jeffrey J, de Andrade, Joao A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013629/
https://www.ncbi.nlm.nih.gov/pubmed/33854398
http://dx.doi.org/10.1177/11795484211006050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013629/
https://www.ncbi.nlm.nih.gov/pubmed/33854398
http://dx.doi.org/10.1177/11795484211006050

Ejemplares similares